2023 U.S. Trials Day 5 Prelims Preview: Walsh Leads a Packed Women's 200 IM Field
The 200 IM sees Alex Walsh, who already qualified for the World Champs via a second-place finish in the 400 IM, come in as the top seed.
Source: swimswam.com
These Trials News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from These Trials. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In These Trials Today - Breaking & Trending Today
CRISPR Therapeutics : Regulation FD Presentation - Form 8-K
A rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust clinical pipeline of investigational small molecule, cell and... | April 3, 2023
Source: marketscreener.com
Vertex Pharmaceuticals Incorporated: Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, with completion of the U.S. submission package in Q1 2023 - EMA and MHRA submissions are on track for Q4 2022 - Exa-cel
Source: finanznachrichten.de
Vertex Pharmaceuticals Incorporated: Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be
Source: finanznachrichten.de
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With
– Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be a one-time functional cure –– Safety profile generally consistent with myeloablative conditioning and autologous stem cell...
Source: pharmiweb.com